Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Its lead RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, it reported positive results from its Phase II experimental RSV infection clinical trial, referred to as the GEMINI study. In April 2008, it initiated a second Phase ...


There are no scholarships at this time


There are no events at this time

Company Data on Alnylam Pharmaceuticals, Inc.
provided by Owler


Alnylam Pharmaceuticals, Inc. is hiring for these positions

Show me: All available jobs